Literature DB >> 1691640

Identification of a human immunodeficiency virus-1 protease cleavage site within the 66,000 Dalton subunit of reverse transcriptase.

M C Graves1, M C Meidel, Y C Pan, M Manneberg, H W Lahm, F Grüninger-Leitch.   

Abstract

The human immunodeficiency virus-1 reverse transcriptase is a heterodimer of related 51 and 66 kDa subunits. The smaller subunit arises by viral protease-catalyzed cleavage of the carboxy-terminal domain of the 66 kDa species. Comparison of the amino acid composition analyses of the isolated 51 kDa and 66 kDa subunits indicates that the carboxyl terminus of 51 kDa is Phe440. This site was confirmed in vitro using purified recombinant protease and a peptide spanning the postulated cleavage area. The sequence surrounding this site does not show significant homology to other protease cleavage sites in the viral gag and pol precursors; thus, this new information may contribute to our understanding of the sequence specificity of the viral protease.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1691640     DOI： 10.1016/0006-291x(90)91670-n

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  11 in total

1.  Reverse transcriptase and protease activities of avian leukosis virus Gag-Pol fusion proteins expressed in insect cells.

Authors:  L Stewart; V M Vogt
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

2.  Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain.

Authors:  Michael E Abram; Michael A Parniak
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein.

Authors:  R L Shoeman; B Höner; T J Stoller; C Kesselmeier; M C Miedel; P Traub; M C Graves
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

4.  Recombinant p51 as antigen in an immune complex transfer enzyme immunoassay of immunoglobulin G antibody to human immunodeficiency virus type 1.

Authors:  K Hashinaka; S Hashida; I Nishikata; A Adachi; S Oka; E Ishikawa
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

5.  Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.

Authors:  Daniel M Held; Jay D Kissel; Sarah J Thacker; Daniel Michalowski; Dayal Saran; Jianfei Ji; Richard W Hardy; John J Rossi; Donald H Burke
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

6.  Reconstitution in vitro of RNase H activity by using purified N-terminal and C-terminal domains of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Z Hostomsky; Z Hostomska; G O Hudson; E W Moomaw; B R Nodes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

7.  The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site.

Authors:  Michael E Abram; Stefan G Sarafianos; Michael A Parniak
Journal:  Retrovirology       Date:  2010-02-01       Impact factor: 4.602

8.  Human immunodeficiency virus type 2 reverse transcriptase activity in model systems that mimic steps in reverse transcription.

Authors:  Klara Post; Jianhui Guo; Kathryn J Howard; Michael D Powell; Jennifer T Miller; Amnon Hizi; Stuart F J Le Grice; Judith G Levin
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

9.  Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase.

Authors:  S F Le Grice; T Naas; B Wohlgensinger; O Schatz
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

10.  Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.

Authors:  D M York; T A Darden; L G Pedersen; M W Anderson
Journal:  Environ Health Perspect       Date:  1993-08       Impact factor: 9.031
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.